MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST000254/mwtabprimary200OKMetabolomicsMass SpectrometryESIFatty Liver DiseaseMus Musculushttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000254Groups:Control | Treatment:10 mM IPA | Strain:WTGroups:Calibration Standard 7 | Treatment:650 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 3 | Treatment:40 ng/ml of IPA | Strain:N/AGroups:Control | Treatment:No IPA | Strain:WTGroups:Calibration Standard 8 | Treatment:1000 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 6 | Treatment:320 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 11 | Treatment:2500 ng/ml of IPA | Strain:N/AGroups:Quality Control Sample 4 | Treatment:1800 ng/ml of IPA | Strain:N/AGroups:Quality Control Sample 3 | Treatment:600 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 1 | Treatment:10 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 9 | Treatment:1500 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 2 | Treatment:20 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 12 | Treatment:3000 ng/ml of IPA | Strain:N/AGroups:Chronic Alcohol Model | Treatment:No IPA | Strain:WTGroups:Quality Control Sample 5 | Treatment:2400 ng/ml of IPA | Strain:N/AGroups:Quality Control Sample 2 | Treatment:200 ng/ml of IPA | Strain:N/AGroups:Chronic Alcohol Model | Treatment:No IPA | Strain:SLGroups:Quality Control Sample 1 | Treatment:30 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 5 | Treatment:160 ng/ml of IPA | Strain:N/AGroups:Calibration Standard 10 | Treatment:2000 ng/ml of IPA | Strain:N/AGroups:Acute Alcohol Model | Treatment:0 mM IPA | Strain:WTGroups:Acute Alcohol Model | Treatment:1 mM IPA | Strain:WTGroups:Calibration Standard 4 | Treatment:80 ng/ml of IPA | Strain:N/AGroups:Control | Treatment:0 mM IPA | Strain:WTGroups:Control | Treatment:1 mM IPA | Strain:WTGroups:Acute Alcohol Model | Treatment:10 mM IPA | Strain:WTBloodUniversity of North CarolinaESI negative ion mode.MetabolomicsWorkbenchdisorder of liver (disorder), Disease of liver, LIVER DIS, Disease, Liver and Intrahepatic Bile Duct Disorder, Liver, experimental, Liver Dysfunction, Liver disorder in pregnancy NOS (disorder), Hepatic Disorder, Unspecified disorder of liver, Dysfunctions, disease or disorder of liver, liver disease or disorder, Concept, Liver disorder NOS, Liver disorder in pregnancy unspecified (disorder), liver disease, Liver Dysfunctions, Liver disorder in pregnancy, Role Concept, Liver disease, Roles, unspecified as to episode of care., Diseases, Role, Concepts, LIVER DISORDER NOS, hepatic disorder, Dysfunction, liver disorder in pregnancy - delivered, liver and intrahepatic bile duct disorder, Liver disorder NOS (disorder), Liver Disease, Liver Diseases, LD - Liver disease, hepatic disease, liver disorder antepartum, Liver disorder in pregnancy - delivered (disorder), methods, Liver disorder in pregnancy (disorder), Disorder of liver (disorder), experimental section, with delivery, [X]Diseases of the liver (disorder), disease of the liver (disorder), Liver Disorder, disorder of liver, disease of liver, experimental procedures, disease of liver [Ambiguous], Hepatopathy, Role Concepts, [X]Diseases of the liver, Disorder of liver, liver disorderWFDC14., WAP3, ESIfalseThe role of microbial metabolites in experimental liver diseaseST00025410090